Brian Siegel
Hayden Investor Relations
Replay available
Laser Photonics Corporation (NASDAQ: LASE) Q3 2024 earnings conference call, held 2024-11-14. Replay captured from the company's public earnings webcast.

Hayden Investor Relations
Chief Executive Officer
Vice President of Finance
Greetings and welcome to the Laser Photonics third quarter 2024 call and webcast. At this time, all participants are in a listen-only mode. If anyone should require operator assistance, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce Brian Siegel with Hayden Investor Relations. Please go ahead. Thank you, operator. With me today are Wayne Topola, Laser Photonics CEO, and Carlos Sardinas, the company's VP of Finance. Any forward-looking statements made during this conference call, whether general or specific in nature, are subject to risks and uncertainties that may cause the actual results to differ materially from those that the company anticipates. These risks and uncertainties include, but are not limited to, the specific risks and uncertainties discussed in the reports the company periodically files with the SEC. Laser Photonics assumes no obligation to either update any forward-looking statements that it has made or may make or to update the factors that may cause actual results to differ materially from those they forecast. I will now turn the call over to Wayne, Laser Photonics Chief Executive Officer. Good morning, everyone, and thank you for joining us today to review Laser Photonics' third quarter results. Before I get into the third quarter, I'm excited to share details about a recent acquisition of Control Microsystems CMS, which was finalized shortly after the close of the quarter. We used a portion of the $3 million in funds we raised in August to make this acquisition, which represents a transformative opportunity for an LPC by expanding our footprint into the healthcare and pharmaceutical industries, particularly in controlled release drug delivery and counterproofin...